Consulta: subjectFacets:"Liver failure"
Registros recuperados: 5
Data/hora: 30/05/2024 11:10:52

Acute hepatitis due to dengue virus in a chronic hepatitis patient
Provedor de dados: 55
Autores: Souza,L.J; Coelho,J.M.C.O.; Silva,E.J.; Abukater,M.; Almeida,F.C.R.; Fonte,A. S.; Souza,L.A.
We present a case of acute hepatitis caused by dengue virus, with a significant increase in aspartate transferase and alanine transferase levels in a chronic hepatitis patient attended at the Cane Sugar Planters Hospital of Campos dos Goytacazes, RJ.
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Dengue; Liver failure; Chronic hepatitis.
Ano: 2008
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000500021

Therapeutic effects of blood purification in treatment of fulminant hepatic failure
Provedor de dados: 55
Autores: Pu,Yunchuan; Yang,Daokun; Mao,Yanqun; Zhang,Ying; Chen,Kaihong.
OBJECTIVES: To evaluate the clinical effects of blood purification for treating fulminant hepatic failure (FHF). METHODS: Thirty-three severe FHF patients with hepatic encephalopathy (HE) above grade III were subjected to a combined blood purification treatment in addition to the comprehensive liver protection therapy. Patients underwent continuous hemofiltration on a daily basis during the daytime followed by sequential treatment with plasma exchange or hemodialysis every 2-3 days. The therapeutic effects of this treatment were evaluated. RESULTS: After treatment with blood purification, restoration of consciousness (those who abandoned the treatment without restoration of consciousness were excluded) was achieved in 6 of 8 cases (75%) in acute liver...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Liver failure; Hepatic encephalopathy; Blood purification; Therapy.
Ano: 2013
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000400007

Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats
Provedor de dados: 56
Autores: Murad,H.A.; Gazzaz,Z.J.; Ali,S.S.; Ibraheem,M.S.
Minimal hepatic encephalopathy is more common than the acute syndrome. Losartan, the first angiotensin-II receptor blocker (ARB), and candesartan, another widely-used ARB, have protected against developing fibrogenesis, but there is no clear data about their curative antifibrotic effects. The current study was designed to examine their effects in an already-established model of hepatic fibrosis and also their effects on the associated motor dysfunction. Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg−1·day−1) intraperitoneally for 2 weeks. The TAA-CLF rats were randomly divided into five groups (n=8) treated orally for 14 days (mg·kg−1·day−1) as follows: TAA (distilled water),...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Candesartan; Hepatic fibrosis; Liver failure; Losartan; Motor dysfunction; Thioacetamide.
Ano: 2017
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001100611

Apolipoprotein and lipid abnormalities in chronic liver failure
Provedor de dados: 56
Autores: Spósito,A.C.; Vinagre,C.G.; Pandullo,F.L; Mies,S.; Raia,S.; Ramires,J.A.F.
Total serum lipids, as well as apolipoproteins A-I (apo A-I) and B (apo B), were determined in 74 patients with chronic liver failure without cholestasis and in 82 normal subjects. The VLDL, LDL and HDL lipid fractions were reduced in the liver failure group by 36%, 24% and 46%, respectively (P&amp;lt;0.001). Apolipoproteins A-I and B were also reduced by 26% and 25%, respectively (P&amp;lt;0.001). However, the reduction of HDL cholesterol (HDLc) was more pronounced than that of apo A-I and the HDLc:apo A-I ratio was significantly lower in the liver failure group. After separating these patients into groups with plasma albumin lower than 3.0, between 3.0 and 3.5, and higher than 3.5 g/dl, the HDLc:apo A-I ratio was proportional to plasma albumin, but the...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Chronic liver disease; Liver failure; Apolipoprotein A; Apolipoprotein B; LCAT; HDL cholesterol; VLDL cholesterol; Lipid metabolism.
Ano: 1997
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001100004

Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases
Provedor de dados: 56
Autores: Wei,Xinhuan; Yu,Haibin; Zhao,Peng; Xie,Li; Li,Li; Zhang,Jing.
Regucalcin is a soluble protein that is principally expressed in hepatocytes. Studies of regucalcin have mainly been conducted in animals due to a lack of commercially available kits. We aimed to develop an enzyme-linked immunosorbent assay (ELISA) to quantify serum regucalcin in patients with hepatitis B virus (HBV)-related disease. High-titer monoclonal antibodies and a polyclonal antibody to regucalcin were produced, a double-antibody sandwich ELISA method was established, and serum regucalcin was determined in 47 chronic hepatitis B (CHB) patients, 91 HBV-related acute-on-chronic liver failure (HBV-ACLF) patients, and 33 healthy controls. The ELISA demonstrated an appropriate linear range, and high levels of reproducibility, sensitivity, specificity,...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Regucalcin; Liver injury; Chronic hepatitis B infection; ELISA; Liver failure.
Ano: 2019
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019001000605